CAS: 88889-14-9; Sodium (2S,4S)-4-Cyclohexyl-1-(2-((R)-((S)-2-Methyl-1-(Propionyloxy)Propoxy)(4-Phenylbutyl)Phosphoryl)Acetyl)Pyrrolidine-2-Carboxylate

该化合物是一种主要用于管理高血压和心脏衰竭的抗生素抑制剂,主要用于管理高血压和心脏衰竭.在水解过程中,它形成了活性代谢物Fosinopril,抑制了ACE,导致血管收缩减少和血压降低.Fosinopril 钠的一个主要优势是其双向消除途径,通过肝脏和肾脏途径平等排泄,使其适合肾脏或肝脏损伤的病人.其长半衰期允许每天服药一次,改善病人的合规性.化合物显示高血浆蛋白结合,提高了其药用植物稳定性.还注意到,同其他ACE抑制剂相比,Fosinopril 钠对电解平衡的影响最小.

结构式图片

欧盟法规

C&L通报

合成工艺路线路线简述

  • 86552-32-1 = 88889-14-9 [标题:Reaction Conditions
    标题:Rapid And Efficient Microwave-Assisted Hydrophosphinylation Of Unactivated Alkenes With H-Phosphinic Acids Without Added Metal Or Radical Initiator
    作者:Troupa,Panagiota; Katsiouleri,Georgia; Vassiliou,Stamatia
    参考文献:Synlett 日期:2015 卷标:26(19) 页码:2714-2719

海关参考信息

专利信息


专利号:US-2008287407-A1
优先权日:2003-12-10
标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

专利号:US-7078532-B2
优先权日:2001-04-30
标 题:Process for manufacture of fosinopril sodium
发明人:DUBEY SUSHIL KUMAR; LAHIRI SASWATA; SINGH ANIL VIR
权利人:LUPIN LAB LTD
摘要:The present invention discloses a process for the synthesis of fosinopril as a single desired isomer of high purity in two steps comprising of (a) preparation of fosinopril as a mixture of four diastereomers and (b) separation of the desired isomer from the mixture through formation of alkali metal salts followed by crystallisation.

专利号:US-9757463-B2
优先权日:2012-06-15
标题 :Linear polyester and semi-linear glycidol polymer systems: formulation and synthesis of novel monomers and macromolecular structures
发明人:HARTH EVA M; BEEZER DAIN B; LI GUANGZHAO; SPEARS BENJAMIN R; STEVENS DAVID M
权利人:UNIV VANDERBILT
摘要:Disclosed herein are glycidol-based polymers, nanoparticles, and methods related thereto useful for drug delivery. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

专利号:US-9745419-B2
优先权日:2014-01-24
标 题 :Aqueous polyglycidol synthesis with ultra-low branching
发明人:HARTH EVA M; SPEARS BENJAMIN R
权利人:UNIV VANDERBILT
摘要:Disclosed herein are glycidol-based polymers, nanoparticles, and methods related thereto useful for a variety of applications, including, but not limited to, drug delivery. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

专利号:WO-2024097977-A1
优先权日:2022-11-04
标题:Silk nanoparticle synthesis: tuning size, dispersity, and surface chemistry for drug delivery
发明人:SHAIDANI SAWNAZ; FALCUCCI THOMAS; FOSTER OLIVIA; SAHOO JUGAL KISHORE; HASTURK ONUR; KAPLAN DAVID L; JACOBUS CHARLOTTE S
权利人:TUFTS COLLEGE
摘要:Methods disclosed herein relate to generating silk nanoparticles with a low polydispersity index (PDI). Methods include adding a silk solution dropwise into a volatile solvent that is miscible with water, thereby forming a precipitate-bearing solution and applying shear forces to the precipitate-bearing solution for a length of time sufficient to achieve evaporation of at least 95% of the volatile solvent, thereby producing a population of silk fibroin nanoparticles in water having a polydispersity index (PDI) of 0.35 or less, including but not limited to, a PDI of 0.330 or less, 0.325 or less, 0.315 or less, 0.310 or less, 0.30 or less, 0.275 or less, 0.250 or less, 0.225 or less, or 0.200 or less. Parameters related to silk fibroin molecular weight, silk fibroin concentration, shear force application, and temperature may all be modified to achieve silk nanoparticles of a particular size exhibiting particular PDIs.

专利号:US-2016206743-A1
优先权日:2012-06-15
标题 :Linear Polyester and Semi-Linear Glycidol Polymer Systems: Formulation and Synthesis of Novel Monomers and Macromolecular Structures
浙江华海药业股份有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.huahaipharm.com
电话: 57685016990👤
📞浙江华海药业股份有限公司 ⚠️参考联系方式

销售电话:57685016990
邮箱:pengyanli@huahaipharm.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
上海泽涵生物医药科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.zehanbiopharma.com
电话: 021-61350663 13052117465👤
📞上海泽涵生物医药科技有限公司 ⚠️参考联系方式

销售电话:021-61350663 13052117465
邮箱:sales@zehanbiopharma.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
厦门环华有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.china-sinoway.com
企业联系电话:86-592-5853819👤
📞厦门环华有限公司 ⚠️参考联系方式
联系人:谢先生
电话:86-592-5853819

传真:86-592-5854960
邮箱:xie@china-sinoway.com
通信地址: 厦门厦禾路839号汇成商业中心16楼
邮编: 361004
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:厦门厦禾路839号汇成商业中心16楼
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
台州沃德凯化工原料有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.chinaworldchem.com
企业联系电话:0576-85301198👤
📞台州沃德凯化工原料有限公司 ⚠️参考联系方式
联系人:张先生
电话:0576-85301198
手机:13736201658
传真:0576-85308398
邮箱:sales@chinaworldchem.com
通信地址: 浙江省临海市巾山东路望江银座2单元1001
邮编: 317000
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:浙江省临海市巾山东路望江银座2单元1001
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Zhang DW, Zhang L, Liu JG, Wang CL, Shi DZ, Chen KJ. [Protective effect of fosinopril sodium pretreatment combined with ischemic postconditioning on rat heart underwent myocardial ischemia/reperfusion injury]. Zhonghua Xin Xue Guan Bing Za Zhi. 2010 Jul;38(7):633-7. Chinese. Epub 2007 Dec 4. Epub 2005 Sep 30.

合成参考文献


参考文献:10.2165/00003495-199651050-00006
摘要:Wagstaff AJ, Davis R, McTavish D. Fosinopril: a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension. Drugs. 1996 May;51(5):777–91. doi: 10.2165/00003495-199651050-00006.
参考文献:10.1007/s10822-005-9017-z
摘要:Kuster DJ, Marshall GR. Validated ligand mapping of ACE active site. Journal of Computer-Aided Molecular Design. 2005 Aug;19(8):609–15. doi: 10.1007/s10822-005-9017-z.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知